Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Novel high performance, waterbased “high solids”and bio-based industrial wood coating (NEXT1KOAT)

Framework: FP7 — Capacities
Programme: Research for the benefit of SMEs
Destination: Research for SME associations
Action type: Research for the benefit of specific groups
Countries involved: Slovenia,Spain,Germany,France,Ireland,Spain,Malta,United Kingdom,United Kingdom,United Kingdom
Call:  (FP7-SME-2012, 2012)
Start date: 2013-01-01
End date: 2015-12-31
Duration (months): 36.0
Total project cost (EUR): 2472500.21
EU funding (EUR): 1861000.0
Participants: 15
Project status: CLOSED

The stringent Solvent Emission Directive (1999/13/EC), fully transposed in 2007, imposes limitations of emissions of volatile organic compounds (VOC) due to the use of organic solvents in paints and varnishes. The most economical way of limiting VOC emission is using water-based coating formulas in which water replaces a substantial amount of the organic solvents traditionally used. Unfortunately, water-based formulas have deficient properties in comparison to solvent-based, primarily as a consequence of using water as a solvent: poor wood wetting, high grain raising, longer drying times, foam formation, insufficient glossy aspect, and deficient overall resistance. Coatings (varnishes and paints) are of key importance to the final products of our industries: coatings define the visual aspect and softness of the furniture piece, influencing its effective purchase; also the durability and resistance of a coating is a measure of the quality of the whole piece. The aim of NEXT1KOAT is to give European woodworking and furniture manufacturers a long-lasting solution by developing a first triple system (exterior uses impregnation; interior uses undercoat and topcoat) of one-component (1K) “high solids” (>70%) water-based coatings. NEXT1KOAT will be produced by European SME coating manufacturers due to its affordable chemistry based on seaweed polymers, and it has been designed for European woodworking and furniture small and medium coating installations. NEXT1KOAT will have the following advanced properties: Less water content (30%), reduced drying time and less grain raising, improved wood wetting without the use of surfactants, less foam formation, more glossy final aspect and increased hardness.

Keywords: water-based coating,waterborne coating,wood coating,seaweed,alginic acid,wood coating resin,alkyd,polyurethane
Adopting Hospital Based Health Technology Assessment in EU (ADHOPHTA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Spain,Spain,Denmark,Switzerland,Finland,Estonia,Italy,Austria,Türkiye,Norway
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-09-01
End date: 2015-11-30
Duration (months): 39.0
Total project cost (EUR): 3676199.95
EU funding (EUR): 2828458.0
Participants: 10
Project status: CLOSED

The use of HTA as a part of the decision-making process at national, regional, and international levels has evolved considerably over the past 35 years. However, still an important number of good-value innovative HTs never reach clinical practice while, in many instances, others with no significant added value actually do. This situation can be effectively overcome by approaching HTA at hospital level, notably because hospitals are the main entry level for innovative HTs. To address these challenges, the AdHopHTA project aims at strengthening the use and impact of quality HTA results in hospital settings, making available pragmatic knowledge and tools to boost adoption of hospital based HTA initiatives. The project also aims at creating an adequate ecosystem where formal coordination among existing hospital based HTA initiatives and liaison with national and regional agencies will flourish. AdHopHTA focuses on hospital based HTA, an area not previously addressed by EUnetHTA, and in need of greater attention due to the considerable volume of resources that hospitals mobilise around investments in HTs. Through the 7 work packages, AdHopHTA will achieve the following 4 strategic objectives: 1) To perform a critical analysis of current formally established hospital based HTA initiatives; 2) To provide with a set of principles for best practice in hospital based HTA; 3) To advance a framework for setting a collaboration among current hospital based HTA initiatives and deployment to other interested EU hospitals; and, 4) To promote the collaboration and coordination of hospital HTA initiatives with HTA National/Regional organisations. The final results of AdhoptHTA will be: a) development of guiding principles on best practices for hospital based HTA; b) an accompanying toolkit to facilitate the deployment of such principles; c) the design and set-up of a database for hospital based HTA products in coordination/compatibility with the POP database (EUnetHTA)

Keywords: hta: hospital innovation uptake,hospital hta methodologies,mini-hta,adoption-toolkit,hospital-based hta best practices,hospital-based hta policy impacts,whole system european hta collaboration
Coordinating Action Systems Medicine – Implementation of Systems Medicine across Europe (CASYM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Coordination and support actions
Countries involved: Germany,Germany,Ireland,United Kingdom,Luxembourg,France,Sweden,Sweden,United Kingdom,Slovenia,Iceland,Germany,United Kingdom,Germany,Netherlands,Israel,Italy,France,Germany,Germany
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2017-04-30
Duration (months): 54.0
Total project cost (EUR): 3681759.8
EU funding (EUR): 2996476.6
Participants: 24
Project status: CLOSED

The aim of CASyM is a combined large scale effort to sustainably implement Systems Medicine across Europe. For that purpose CASyM will function as a managing and coordinating platform in bringing together a critical mass of relevant European stakeholders such as Systems Biology scientists, clinicians, programme managers, industry/SMEs as well as healthcare providers and patient organizations. The goal of that initial nucleus of experts is the development of a strategy to implement the Systems Biology approach into medical practice and research within the 4 years duration of CASyM. For this purpose it is essential that the involved communities build a vision and coordinated strategy. Our joint effort gathers extensive experience in the coordination and realization of such a new, large-scale European effort, thereby providing the basis for an advanced future medicine. The output of CASyM will be a conceptual framework defining the remits, milestones, mechanisms and metrics for the implementation of Systems Medicine. The development of this framework will overcome competitive barriers and proceed to produce a European roadmap for Systems Medicine as concerted project result.

Keywords: systems medicine,paradigm shift,road map,coordinated strategy,interdisciplinary approach,multidisciplinary training,data management,innovation,p4 medicine,improved drug discovery
Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Netherlands,Germany,United Kingdom,Germany,United Kingdom,France,France,Belgium,Italy,United Kingdom,Iceland,France,Netherlands,Australia,Germany,United States,Sweden
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-10-01
End date: 2017-09-30
Duration (months): 60.0
Total project cost (EUR): 16846062.83
EU funding (EUR): 12000000.0
Participants: 19
Project status: CLOSED

Neurodegenerative (ND) and neuromuscular (NM) disease is one of the most frequent classes of rare diseases, affecting life and mobility of 500,000 patients in Europe and millions of their caregivers, family members and employers. This NEUROMICS project brings together the leading research groups in Europe, five highly innovative SMEs and relevant oversea experts using the most sophisticated Omics technologies to revolutionize diagnostics and to develop pathomechanism-based treatment for ten major ND and NM diseases. Specifically we aim to: (i) use next generation WES to increase the number of known gene loci for the most heterogeneous disease groups from about 50% to 80%, (ii) increase patient cohorts by large scale genotyping by enriched gene variant panels and NGS of so far unclassified patients and subsequent phenotyping, (iii) develop biomarkers for clinical application with a strong emphasis on presymptomatic utility and cohort stratification, (iv) combine -omics approaches to better understand pathophysiology and identify therapeutic targets, (v) identify disease modifiers in disease subgroups cohorts with extreme age of onset (vi) develop targeted therapies (to groups or personalized) using antisense oligos and histone deacetylase inhibitors, translating the consortiums expertise in clinical development from ongoing trials toward other disease groups, notably the PolyQ diseases and other NMD. To warrant that advances affect a large fraction of patients we limited the selection to a number of major categories, some of which are in a promising stage of etiological and therapeutic research while some others are in great need of further classification. The efforts will be connected through a NEUROMICS platform for impact, communication and innovation that will provide tools and procedures for ensuring trial-readiness, WP performance, sustainability, interaction with the chosen Support IRDiRC and RD-Connect project and involvement of stakeholders in the NDD/NMD field.

Keywords: neuromuscular and neurodegenerative disease,omics technologies,large scale diagnostics,pathomechanism-based treatment
Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation (BIO-DRIM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,France,United Kingdom,United Kingdom,Spain,Czechia,Netherlands,Germany,Germany,France,Germany,Italy,Germany,Germany
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2018-10-31
Duration (months): 72.0
Total project cost (EUR): 7920189.34
EU funding (EUR): 5989000.0
Participants: 17
Project status: CLOSED

Organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure. Incomplete control of chronic allograft injury but also the adverse effects of long-term immunosuppression (IS) continue to challenge the long-term success of transplantation. The paradigm is shifting from increasing “net”-IS by novel drugs to the concept of minimizing long-term IS as early as possible. However, data were almost completely generated by “trial-and-error” observational studies. It suggests an unmet need to stratify transplant (Tx) patients regarding their immunological responsiveness to the allograft and their respective individual need of IS. The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as “operationally tolerant” by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings–Indices of Tolerance (IOT) and RISET but also of other international groups.

Keywords: organ transplantation,immunosuppression,biomarkers,biomarker-driven strategies,personalizing immunosuppression,investigator-driven biomarker clinical trials,biomarker-based stratification
Concurrent Tuberculosis and Diabetes Mellitus; unraveling the causal link, and improving care (TANDEM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Netherlands,Germany,Netherlands,South Africa,New Zealand,Romania,Netherlands,Peru,Indonesia,Germany
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-02-01
End date: 2017-07-31
Duration (months): 54.0
Total project cost (EUR): 7988142.0
EU funding (EUR): 5998496.0
Participants: 12
Project status: CLOSED

Diabetes (DM) triples the risk of developing tuberculosis (TB). Consequently, the alarming growth of type 2 DM in TB endemic countries and among people originating from TB-endemic countries poses a serious threat to global TB control. This project addresses the scarce evidence for many of the recently advocated guidelines for care and control of TB and DM, as well as our lack of understanding of the mechanisms underlying the effect of DM on TB susceptibility and treatment outcome. We will use a comprehensive and integrated approach combining clinical, epidemiological and cutting edge expertise in laboratory sciences, bringing together a multi-disciplinary consortium linking field sites in Romania, Peru, South Africa and Indonesia, with leading laboratories in Germany, United Kingdom and the Netherlands. We will define the optimal and most cost-effective ways of screening TB patients for DM diabetes, and determine the prevalence of DM among TB patients and of TB in DM patients in the four countries. With regard to treatment, we will determine the level of DM management required during and after TB treatment, the safety and pharmacokinetics of metformin when combined with rifampicin, and the effect of hyperglycemia control on TB treatment outcome. To help establish the cellular basis and immunological pathways underlying the link between DM and TB we will provide new data on: gene expression data of TB patients with and without DM; ex vivo and in vitro Mycobacterium tuberculosis stimulation data of different cell types, including macrophage subsets and adipocytes in the presence of high glucose and insulin; data regarding the role of common and more rare genetic variants in the combined susceptibility to TB and type 2 DM; and relevant functional genomics experiments. In summary, this project is expected to have significant impact both in improving basic knowledge on the link between TB and DM, as well as on prevention, therapeutic management and prognosis of TB-DM.

Keywords: tuberculosis,diabetes,biomarkers,functional genomics,gene expression,treatment,glycaemic control
Metagenomics in Cardiometabolic Diseases (METACARDIS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,United Kingdom,Denmark,Germany,Sweden,Belgium,Germany,France,France,Germany
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2018-10-31
Duration (months): 72.0
Total project cost (EUR): 23132095.8
EU funding (EUR): 11999992.0
Participants: 16
Project status: CLOSED

METACARDIS applies a systems medicine multilevel approach to identify biological relationships between gut microbiota, assessed by metagenomics, and host genome expression regulation, which will improve understanding and innovative care of cardiometabolic diseases (CMD) and their comorbidities. CMD comprise metabolic (obesity, diabetes) and heart diseases characterized by a chronic evolution in ageing populations and costly treatments. Therapies require novel integrated approaches taking into account CMD natural evolution. METACARDIS associates European leaders in metagenomics, who have been successful in establishing the structure of the human microbiome as part of the EU FP7 MetaHIT consortium, clinical and fundamental researchers, SME, patients associations and food companies to improve the understanding of pathophysiological mechanisms, prognosis and diagnosis of CMD. We will use next-generation sequencing technologies and high throughput metabolomic platforms to identify gut microbiota- and metabolomic-derived biomarkers and targets associated with CMD risks. The pathophysiological role of these markers will be tested in both preclinical models and replication cohorts allowing the study of CMD progression in patients collected in three European clinical centres of excellence. Their impact on host gene transcription will be characterised in patients selected for typical features of CMD evolution. Application of computational models and visualisation tools to complex datasets combining clinical information, environmental patterns and gut microbiome, metabolome and transcriptome data is a central integrating component in the research, which will be driven by world leaders in metagenomic and functional genomic data analysis. These studies will identify novel molecular targets, biomarkers and predictors of CMD progression, paving the way for personalized medicine in CMD.

Keywords: cardiometabolic diseases,risk,metagenomics,metabolomics transcriptomics clinical phenotyping,computational biology,modeling,integrated risk factors
Improving Outcome of Necrotizing Fasciitis: Elucidation of Complex Host and Pathogen Signatures that Dictate Severity of Tissue Infection (INFECT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Sweden,Denmark,Sweden,Sweden,Norway,United States,Germany,Netherlands,France,Germany,Israel,Austria,United Kingdom
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-01-01
End date: 2018-06-30
Duration (months): 66.0
Total project cost (EUR): 15680322.69
EU funding (EUR): 11913591.0
Participants: 16
Project status: CLOSED

The overall goal with INFECT is to advance our understanding of the pathophysiological mechanisms, prognosis, and diagnosis of the multifactorial highly lethal NSTIs. The fulminant course of NSTIs (in the order of hours) demands immediate diagnosis and adequate interventions in order to salvage lives and limbs. However, diagnosis and management are difficult due to heterogeneity in clinical presentation, in co-morbidities and in microbiological aetiology. Thus, there is an urgent need for novel diagnostic and therapeutic strategies in order to improve outcome of NSTIs. To achieve this, a comprehensive and integrated knowledge of diagnostic features, causative microbial agent, treatment strategies, and pathogenic mechanisms (host and bacterial disease traits and their underlying interaction network) is required. INFECT is designed to obtain such insights through an integrated systems biology approach in patients and different clinically relevant experimental models. Specific objectives of INFECT are to: 1. Unravel specific mechanisms underlying diseases signatures though a bottom-up systems approach applied to clinically relevant experimental settings 2. Apply a top-down systems biology approach to NSTI patient samples to pin-point key host and pathogen factors involved in the onset and development of infection 3. Identify and quantify disease signatures and underlying networks that contribute to disease outcome 4. Exploit identified disease traits for the innovation of optimized diagnostic tools 5. Translate the advanced knowledge generated into evidence-based guidelines for classification and management, and novel therapeutic strategies We have gathered a team of multidisciplinary researchers, clinicians, SMEs and a patient organization, each with a unique expertise, technical platform and/or model systems that together provide the means to successfully conduct the multifaceted research proposed and efficiently disseminate/exploit the knowledge obtained.

Keywords: microbial infections,necrotizing soft tissue infection,host-pathogen interactions,systems biology,integrated modelling,immunomodulatory strategies,diagnostics
Circulating Tumor Cells TheRapeutic APheresis: a novel biotechnology enabling personalized therapy for all cancer patients (CTCTRAP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Netherlands,France,United Kingdom,Germany,Germany,Hungary,Italy,Estonia,Netherlands,Germany,Germany
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-09-01
End date: 2016-08-31
Duration (months): 48.0
Total project cost (EUR): 8321935.0
EU funding (EUR): 6000000.0
Participants: 12
Project status: CLOSED

Chemotherapy is slowly being supplemented by a new generation of drugs that recognize specific targets in or on cancer cells and has proven to be more effective with markedly fewer side effects. During the course of the disease alternative oncogenic signaling pathways take over inevitably leading to drug resistance. As a consequence renewed tumor analysis is required to redefine the optimal treatment regiment. However a biopsy can frequently not be obtained without risk and or discomfort to the patient. Circulating tumor cells (CTC) may circumvent this problem. CTC refer to cells that detach from a primary tumor or metastatic site, circulate in the peripheral blood and may form metastasis. CTC represent a "liquid biopsy" that can be used to tailor treatment for individual patients. CTC are however rare and can only be obtained for further characterization in a small fraction of patients. In the CTCtrap consortium universities, research institutions and SMEs are linked in a common effort, starting from the simple, but innovative view of using Therapeutic Apheresis (TA), as a way to collect CTC from peripheral blood in cancer patients. A new TA column will be developed to capture CTC and then reintroduce the blood devoid of tumor cells back into the body with the promise to obtain CTC in all patients at risk for recurrence or diagnosed with metastatic disease. The molecular characterization of these CTC is expected to gather new knowledge on metastasis' mechanism, provide a risk assessment and the optimal therapy choice during the course of the disease of cancer patients. The new knowledge on CTC heterogeneity within cancer type and within individuals will allow for the tuning of CTCapheresis to specific cancer types. Prospective pilot studies will be setup to investigate the feasibility of the CTCapheresis in the clinic and their potential therapeutic benefit. Success of CTCapheresis will lead to a radical change in the diagnosis and treatment of solid tumors.

Keywords: circulating tumor cells (ctc),therapeutic apheresis (ta),targeted therapy,molecular genotyping